‘Study of the Nanocomposite Mo2C(1-x)-TiC(x)-SWCNTs by Field Actived Sparck Plasma Sintering Process’

International audienc

Study of the Nanocomposite Mo2C(1-x)-TiC(x)-SWCNTs by Field Actived Sparck Plasma Sintering Process’

International audienc

‘Study of the High Performance Ceramic-Matrix Composites (CMC’s) byCombustion in the TiO2-Al-C System’

International audienc

The diagnostic value of the functional lumen imaging probe versus high-resolution anorectal manometry in patients with fecal incontinence

International audienc

Nanocomposite Beta Nb50Ti based SWCNTs by FAST-SPS-FCT

International audienceThe synthesis of β-type phase NbxTi (x= 50 at%) / SWCNTs (Single Walled Carbon Nanotubes) intermetallic matrix nanocomposite by mechanical alloying to ensure the effective distribution of (SWCNTs) within the matrix. It has been stated by several researchers that during ball-milling of NbxTi (x =50 at%) powder mixtures, Nb-Ti intermetallic compound formation occurs either gradually along milling time of mechanical allowing (MA), or suddenly through amechanically self-propagating reaction (MSPR), which occurs after a ignition time of MA. For this purpose, 0.4and 0.8 at% of SWNTs was added to the powder mixture after the completion of reactionbetween Nb and Ti. The obtained powders Nb50Ti intermetallic compound mixed with SWCNTs powder and then was also ball-milled. Bulk samples were compacted and then sintered by (FAST-SPS-FCT) method (Field Assisted Sintering Technics-Sparck Plasma Sintering- Furnace, Advanced Ceramics for High-Temperature) at the temperature range (1273-1473 °K) with some time that retained the integrity of SWNTs in the intermetallic matrix.Structural and mechanical and vibronic changes of the nanocomposites were investigated by X-ray diffractometery (XRD). Field emission scanning electron microscopy (FESEM) micrographs showed that the offered MA approach caused the SWNTs to be uniformly embedded in the in situ synthesized NbTi intermetallic matrix. Meanwhile better distribution of SWCNTs resulted in higher density of FAST-SPS-FCT bulk nanocomposite as well higher hardness up to 2.75GPa compared to 2.4 of Nb50Ti intermetallic alloy obtained after MA time. The total porosity, compressive strength, and compressive elastic modulus of the FAST-SPS-FCT manufactured material were determined as 7%, 600 MPa, and 120 MPa, respectively. The alloy’s and its intermetallic nanocomposite have Young’s elastic modulus is comparable to that of healthy cancellous bone which makes it applicable in the biomedical field. The in vitro biocomptability will be performed in the near future. The comparable results for the FAST-SPS-FCT nanocomposites were 3%, 650 MPa, and 130 MPa. The alloy’s elastic modulus is comparable to that of healthy cancellous bone. This difference in mechanical properties results from different porosity and phase composition of the bot β-phase NbxTi (x= 50 at%) and NbxTi (x= 50 at%)/SWCNTs intermetallic matrix nanocomposite. More other nanotechnologies applications of the nanocomposite will be focused in the study of the superconducting type I for the ITER Poloidal Field Coils by measuring of Jc (T, B) characteristics

Clinical and ultrasonographic evaluation of the window of opportunity for retreatment with rituximab in rheumatoid arthritis patients from a multicentre real-life study

International audienceObjective To determine a potential window of opportunity for retreatment with rituximab in patients with rheumatoid arthritis (RA) from a multicentre longitudinal real-life study based on tight monitoring with ultrasonography (US).Methods Thirty RA patients treated with rituximab were included. US parameters were collected at each time (8 visits) of the 18-month follow-up, notably the global score of power Doppler (PD) activity. Clinical relapse was defined as a DAS28 ESR of >3.2 after 6 months in responders while US relapse was defined as an increase of =20% of the global score of PD activity. The decision of retreatment was based exclusively on clinical findings.Results A total of 29 patients were analysed (mean (SD) age: 57.2 (12.2) years; female gender: 66%). The mean (SD) PD score decreased from 8.8 (5.2) at baseline to 4.9 (4.3) at 6 months (p <0.0001). A clinical response was observed at Month 4 or Month 6 for 93% of patients. A total of 19 patients had a first clinical relapse (with or without US relapse) after Month 6 (18 of them were retreated with rituximab). Among 10 patients without clinical relapse, 3 had US relapse (only one was retreated) and 7 had no US relapse (but 4 were retreated).Conclusion This study highlights a great heterogeneity in terms of sequence of clinical relapse, US relapse and retreatment in RA patients receiving rituximab. Therefore, US monitoring does not seem to be relevant to determine the best time for retreatment with rituximab

Clinical and ultrasonographic evaluation of the window of opportunity for retreatment with rituximab in rheumatoid arthritis patients from a multicentre real-life study

Objective To determine a potential window of opportunity for retreatment with rituximab in patients with rheumatoid arthritis (RA) from a multicentre longitudinal real-life study based on tight monitoring with ultrasonography (US).Methods Thirty RA patients treated with rituximab were included. US parameters were collected at each time (8 visits) of the 18-month follow-up, notably the global score of power Doppler (PD) activity. Clinical relapse was defined as a DAS28 ESR of >3.2 after 6 months in responders while US relapse was defined as an increase of =20% of the global score of PD activity. The decision of retreatment was based exclusively on clinical findings.Results A total of 29 patients were analysed (mean (SD) age: 57.2 (12.2) years; female gender: 66%). The mean (SD) PD score decreased from 8.8 (5.2) at baseline to 4.9 (4.3) at 6 months (p <0.0001). A clinical response was observed at Month 4 or Month 6 for 93% of patients. A total of 19 patients had a first clinical relapse (with or without US relapse) after Month 6 (18 of them were retreated with rituximab). Among 10 patients without clinical relapse, 3 had US relapse (only one was retreated) and 7 had no US relapse (but 4 were retreated).Conclusion This study highlights a great heterogeneity in terms of sequence of clinical relapse, US relapse and retreatment in RA patients receiving rituximab. Therefore, US monitoring does not seem to be relevant to determine the best time for retreatment with rituximab

Investigation of a vanA linezolid- and vancomycin-resistant Enterococcus faecium outbreak in the Southwest Indian Ocean (Reunion Island)

International audienceIntroduction: Dual resistance to linezolid and glycopeptides is a milestone reached by certain extensively drug-resistant (XDR) enterococci. This paper describes the molecular and epidemiological investigations of a linezolid-resistant and vancomycin-resistant Enterococcus faecium (E. faecium) (LVREf) outbreak in the French overseas territory of Reunion Island (Indian Ocean). Methods: All vancomycin-resistant Enterococcus (VRE) isolates detected on Reunion Island between 2015 and 2019 were included in the study. The VRE isolates were phenotypically characterised and genetically explored by whole-genome sequencing (WGS). Results: Sixteen vancomycin-resistant E. faecium (VREf) isolates were retrieved between 2015 and 2019. Seven isolates obtained in 2019 were involved in the outbreak. These seven LVREf isolates from the 2019 outbreak at the University Hospital of Reunion Island (UHRI) were suspected to be related to a linezolid-susceptible VREf strain imported from India. An epidemiological link was highlighted for six of the seven outbreak cases. All the LVREf outbreak isolates were obtained from rectal swabs (colonisation) and resistant to vancomycin (MIC &gt; 128 mg/L) and linezolid (MIC 8–32 mg/L); one isolate was also resistant to daptomycin (MIC 8 mg/L). The seven outbreak isolates were positive for the vanA and optrA genes and belonged to ST761. Conclusions: These results argue for the strict application of control and prevention measures for VRE clones at high risk of spread, particularly in areas such as Reunion Island where the risk of importation from the Indian subcontinent is high. The regional spread of optrA linezolid-resistance genes in VRE isolates is a matter of concern, due to possibility of treatment failure. © 2022 The Author(s